Wall Street Zen Upgrades Burning Rock Biotech (NASDAQ:BNR) to Buy

Burning Rock Biotech (NASDAQ:BNR) was upgraded by Wall Street Zen from a “hold” rating to a “buy” rating in a research note issued on Saturday.

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Burning Rock Biotech in a research note on Wednesday, October 8th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock presently has a consensus rating of “Sell”.

Burning Rock Biotech Stock Performance

Shares of Burning Rock Biotech stock opened at $32.01 on Friday. The company has a quick ratio of 2.91, a current ratio of 3.14 and a debt-to-equity ratio of 0.03. The stock’s fifty day moving average is $19.64 and its two-hundred day moving average is $12.21. Burning Rock Biotech has a 52 week low of $2.18 and a 52 week high of $34.79. The company has a market capitalization of $344.43 million, a PE ratio of -19.28 and a beta of 1.25.

Institutional Trading of Burning Rock Biotech

Institutional investors and hedge funds have recently made changes to their positions in the company. China Universal Asset Management Co. Ltd. bought a new position in Burning Rock Biotech during the 3rd quarter worth about $26,000. Prospera Financial Services Inc purchased a new stake in shares of Burning Rock Biotech in the 3rd quarter worth approximately $214,000. Finally, Crcm LP lifted its position in shares of Burning Rock Biotech by 13.8% in the 3rd quarter. Crcm LP now owns 221,575 shares of the company’s stock worth $1,917,000 after purchasing an additional 26,809 shares during the period. 30.03% of the stock is currently owned by institutional investors.

About Burning Rock Biotech

Burning Rock Biotech (NASDAQ: BNR) is a precision oncology company specializing in the development and commercialization of next-generation sequencing (NGS)–based cancer diagnostics. The company’s core business revolves around liquid biopsy tests, which analyze circulating tumor DNA (ctDNA) from blood samples to detect genetic mutations associated with various solid tumors. By enabling noninvasive profiling of tumor genomics, Burning Rock Biotech aims to guide personalized therapy decisions and monitor treatment response in cancer patients.

Founded in 2014 and headquartered in Guangzhou, China, Burning Rock Biotech launched its first clinical services in the mid-2010s and subsequently expanded its laboratory network across major Chinese cities.